Research programme: systemic lupus erythematosus and lupus nephritis therapeutics - EMD Serono/Massachusetts General Hospital
Latest Information Update: 28 Dec 2021
At a glance
- Originator EMD Serono; Massachusetts General Hospital
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lupus nephritis; Systemic lupus erythematosus
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Lupus-nephritis in USA
- 28 Dec 2021 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in USA
- 03 Nov 2017 Preclinical trials in Lupus nephritis in USA (unspecified route)